Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-001 First-in-Human Study
NCT04737486Phase 1Completed
- Sponsor
- Vasomune Therapeutics, Inc.
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pegevongitide in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (4 arms), sponsored by Vasomune Therapeutics, Inc. Primary endpoint: Participants experiencing drug-related adverse events at 8 days. Started Dec 2020; status: completed.
02
Drugs
pegevongitide
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04737486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04737486.